Comerica Bank Reduces Stock Position in Kenvue Inc. $KVUE

Key Points

• Comerica Bank reduced its holdings in Kenvue Inc. by 1.8%, now owning 646,869 shares valued at approximately $15.51 million.
• Kenvue announced a quarterly dividend increase to $0.2075, reflecting a yield of 3.9%, with the ex-dividend date set for August 13th.
• The company's quarterly earnings report showed EPS of $0.29, surpassing estimates, but its revenue declined by 4% year-over-year, totaling $3.84 billion.

Comerica Bank cut its stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 1.8% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 646,869 shares of the company's stock after selling 12,094 shares during the period. Comerica Bank's holdings in Kenvue were worth $15,512,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of KVUE. Cambridge Investment Research Advisors Inc. raised its position in shares of Kenvue by 4.0% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 106,140 shares of the company's stock valued at $2,545,000 after purchasing an additional 4,034 shares during the period. IFP Advisors Inc raised its position in shares of Kenvue by 25.3% during the 1st quarter. IFP Advisors Inc now owns 15,278 shares of the company's stock valued at $369,000 after purchasing an additional 3,081 shares during the period. Starboard Value LP bought a new stake in shares of Kenvue during the 4th quarter valued at $467,864,000. Kingswood Wealth Advisors LLC bought a new stake in shares of Kenvue during the 1st quarter valued at $413,000. Finally, Cooper Investors PTY Ltd. raised its position in shares of Kenvue by 39.7% during the 1st quarter. Cooper Investors PTY Ltd. now owns 858,076 shares of the company's stock valued at $20,577,000 after purchasing an additional 244,043 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Price Performance

Shares of NYSE KVUE traded up $0.18 during mid-day trading on Friday, hitting $20.72. 10,307,391 shares of the company's stock traded hands, compared to its average volume of 17,296,208. The company's 50-day moving average is $21.46 and its two-hundred day moving average is $22.44. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.68. The company has a market capitalization of $39.76 billion, a P/E ratio of 27.99, a PEG ratio of 2.97 and a beta of 0.83. Kenvue Inc. has a 1 year low of $19.75 and a 1 year high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.01. The firm had revenue of $3.84 billion for the quarter, compared to analysts' expectations of $3.94 billion. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The business's revenue was down 4.0% compared to the same quarter last year. During the same period in the prior year, the company earned $0.32 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, equities analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Shareholders of record on Wednesday, August 13th were given a dividend of $0.2075 per share. This represents a $0.83 dividend on an annualized basis and a yield of 4.0%. This is a positive change from Kenvue's previous quarterly dividend of $0.21. The ex-dividend date was Wednesday, August 13th. Kenvue's dividend payout ratio (DPR) is presently 112.16%.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Citigroup cut their price objective on shares of Kenvue from $24.50 to $22.00 and set a "neutral" rating for the company in a report on Tuesday, July 15th. Canaccord Genuity Group cut their price objective on shares of Kenvue from $29.00 to $26.00 and set a "buy" rating for the company in a report on Friday, August 8th. Zacks Research raised shares of Kenvue to a "strong sell" rating in a report on Monday, August 11th. Royal Bank Of Canada cut their price objective on shares of Kenvue from $24.00 to $22.00 and set a "sector perform" rating for the company in a report on Friday, August 8th. Finally, UBS Group dropped their price target on Kenvue from $25.00 to $23.00 and set a "neutral" rating for the company in a research note on Thursday, July 17th. Five research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $24.38.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.